IMMUNITYBIO, INC. Selling, General and Administrative Expense
IMMUNITYBIO, INC. (IBRX) reported Selling, General and Administrative Expense of $168.78 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-03-03
- IMMUNITYBIO, INC. selling, general and administrative expense for the quarter ending 2024-12-31 was $41.73M, a 26.04% increase year-over-year.
- IMMUNITYBIO, INC. selling, general and administrative expense for the quarter ending 2024-09-30 was $35.92M, a 12.89% increase year-over-year.
- IMMUNITYBIO, INC. selling, general and administrative expense for the quarter ending 2024-06-30 was $49.25M, a 53.82% increase year-over-year.
- IMMUNITYBIO, INC. selling, general and administrative expense for the quarter ending 2024-03-31 was $41.88M, a 28.18% increase year-over-year.
- IMMUNITYBIO, INC. selling, general and administrative expense for fiscal 2024 was $168.78M, a 30.21% increase from fiscal 2023.
- IMMUNITYBIO, INC. selling, general and administrative expense for fiscal 2023 was $129.62M, a 26.20% increase from fiscal 2022.
- IMMUNITYBIO, INC. selling, general and administrative expense for fiscal 2022 was $102.71M, a 24.06% decline from fiscal 2021.
- IMMUNITYBIO, INC. selling, general and administrative expense for fiscal 2021 was $135.26M, a 89.65% increase from fiscal 2020.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $41.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $77.65M derived: sum of 2 quarters · filed 2025-03-03 | $126.90M derived: sum of 3 quarters · filed 2025-03-03 | $168.78M 10-K · filed 2025-03-03 | ||||
| 2024-09-30 | $35.92M 10-Q · filed 2024-11-12 | $85.17M derived: sum of 2 quarters · filed 2024-11-12 | $127.05M 10-Q · filed 2024-11-12 | $160.16M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2024-06-30 | $49.25M 10-Q · filed 2024-08-12 | $91.14M 10-Q · filed 2024-08-12 | $124.25M derived: sum of 3 quarters · filed 2025-03-03 | $156.06M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2024-03-31 | $41.88M 10-Q · filed 2024-05-09 | $75.00M derived: sum of 2 quarters · filed 2025-03-03 | $106.81M derived: sum of 3 quarters · filed 2025-03-03 | $138.83M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-12-31 | $33.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $64.93M derived: sum of 2 quarters · filed 2025-03-03 | $96.94M derived: sum of 3 quarters · filed 2025-03-03 | $129.62M 10-K · filed 2025-03-03 | ||||
| 2023-09-30 | $31.82M 10-Q · filed 2024-11-12 | $63.83M derived: sum of 2 quarters · filed 2024-11-12 | $96.51M 10-Q · filed 2024-11-12 | $122.72M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | $32.02M 10-Q · filed 2024-08-12 | $64.69M 10-Q · filed 2024-08-12 | $90.91M derived: sum of 3 quarters · filed 2025-03-03 | $110.22M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $32.68M 10-Q · filed 2024-05-09 | $58.89M derived: sum of 2 quarters · filed 2025-03-03 | $78.20M derived: sum of 3 quarters · filed 2025-03-03 | $94.78M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $26.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $45.52M derived: sum of 2 quarters · filed 2025-03-03 | $62.10M derived: sum of 3 quarters · filed 2025-03-03 | $102.71M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $19.31M 10-Q · filed 2023-11-09 | $35.88M derived: sum of 2 quarters · filed 2023-11-09 | $76.49M 10-Q · filed 2023-11-09 | $104.40M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | $16.57M 10-Q · filed 2023-08-08 | $57.18M 10-Q · filed 2023-08-08 | $85.09M derived: sum of 3 quarters · filed 2024-03-19 | $114.72M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | $40.61M 10-Q · filed 2023-05-11 | $68.52M derived: sum of 2 quarters · filed 2024-03-19 | $98.14M derived: sum of 3 quarters · filed 2024-03-19 | $130.59M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | $27.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $57.54M derived: sum of 2 quarters · filed 2024-03-19 | $89.98M derived: sum of 3 quarters · filed 2024-03-19 | $135.26M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | $29.63M 10-Q · filed 2022-11-09 | $62.07M derived: sum of 2 quarters · filed 2022-11-09 | $107.34M 10-Q · filed 2022-11-09 | $131.23M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-06-30 | $32.45M 10-Q · filed 2022-08-08 | $77.72M 10-Q · filed 2022-08-08 | $101.60M derived: sum of 3 quarters · filed 2024-03-19 | $121.20M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-03-31 | $45.27M 10-K · filed 2024-03-19 | $69.16M derived: sum of 2 quarters · filed 2024-03-19 | $88.75M derived: sum of 3 quarters · filed 2024-03-19 | $107.10M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2020-12-31 | $23.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $43.48M derived: sum of 2 quarters · filed 2023-03-01 | $61.83M derived: sum of 3 quarters · filed 2023-03-01 | $71.32M 10-K · filed 2023-03-01 | $27.25M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $19.60M 10-Q · filed 2021-11-12 | $4.71M 10-Q · filed 2020-11-09 | $37.94M derived: sum of 2 quarters · filed 2021-11-12 | $47.44M 10-Q · filed 2021-11-12 | $16.60M 10-Q · filed 2020-11-09 | $79.94M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $18.35M 10-Q · filed 2021-08-12 | $6.52M 10-Q · filed 2020-08-07 | $27.84M 10-Q · filed 2021-08-12 | $11.89M 10-Q · filed 2020-08-07 | $60.35M derived: sum of 3 quarters · filed 2022-03-01 | $64.37M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $9.49M 10-Q · filed 2021-05-14 | $5.37M 10-Q · filed 2020-05-11 | $42.00M derived: sum of 2 quarters · filed 2022-03-01 | $46.02M derived: sum of 3 quarters · filed 2022-03-01 | $50.21M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $32.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $36.53M derived: sum of 2 quarters · filed 2022-03-01 | $40.71M derived: sum of 3 quarters · filed 2022-03-01 | $46.46M 10-K · filed 2022-03-01 | $18.07M 10-K · filed 2020-03-25 | |||
| 2019-09-30 | $4.03M 10-Q · filed 2020-11-09 | $8.21M derived: sum of 2 quarters · filed 2020-11-09 | $13.95M 10-Q · filed 2020-11-09 | $19.20M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | $4.18M 10-Q · filed 2020-08-07 | $9.92M 10-Q · filed 2020-08-07 | $15.17M derived: sum of 3 quarters · filed 2021-03-04 | $24.75M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | $5.74M 10-Q · filed 2020-05-11 | $10.99M derived: sum of 2 quarters · filed 2021-03-04 | $20.57M derived: sum of 3 quarters · filed 2021-03-04 | $34.16M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2018-12-31 | $5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $14.83M derived: sum of 2 quarters · filed 2021-03-04 | $28.42M derived: sum of 3 quarters · filed 2021-03-04 | $42.72M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | $9.58M 10-Q · filed 2019-11-05 | $23.17M derived: sum of 2 quarters · filed 2019-11-05 | $37.47M 10-Q · filed 2019-11-05 | $50.86M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-06-30 | $13.59M 10-Q · filed 2019-08-06 | $27.89M 10-Q · filed 2019-08-06 | $41.28M derived: sum of 3 quarters · filed 2020-03-25 | $54.66M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-03-31 | $14.30M 10-Q · filed 2019-05-08 | $27.68M derived: sum of 2 quarters · filed 2020-03-25 | $41.06M derived: sum of 3 quarters · filed 2020-03-25 | $55.19M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2017-12-31 | $13.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $26.77M derived: sum of 2 quarters · filed 2020-03-25 | $40.89M derived: sum of 3 quarters · filed 2020-03-25 | $57.12M 10-K · filed 2020-03-25 | ||||
| 2017-09-30 | $13.38M 10-Q · filed 2018-11-07 | $27.51M derived: sum of 2 quarters · filed 2018-11-07 | $43.74M 10-Q · filed 2018-11-07 | $59.45M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-06-30 | $14.13M 10-Q · filed 2018-08-06 | $30.36M 10-Q · filed 2018-08-06 | $46.07M derived: sum of 3 quarters · filed 2019-03-13 | $70.49M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-03-31 | $16.23M 10-Q · filed 2018-05-07 | $31.94M derived: sum of 2 quarters · filed 2019-03-13 | $56.36M derived: sum of 3 quarters · filed 2019-03-13 | $84.95M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2016-12-31 | $15.71M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $40.14M derived: sum of 2 quarters · filed 2019-03-13 | $68.72M derived: sum of 3 quarters · filed 2019-03-13 | $95.39M 10-K · filed 2019-03-13 | ||||
| 2016-09-30 | $24.42M 10-Q · filed 2017-11-07 | $53.01M derived: sum of 2 quarters · filed 2017-11-07 | $79.68M 10-Q · filed 2017-11-07 | $105.52M derived: sum of 4 quarters · filed 2017-11-07 | ||||
| 2016-06-30 | $28.59M 10-Q · filed 2017-08-07 | $55.26M 10-Q · filed 2017-08-07 | $81.09M derived: sum of 3 quarters · filed 2017-08-07 | $122.90M derived: sum of 4 quarters · filed 2017-08-07 | ||||
| 2016-03-31 | $26.67M 10-Q · filed 2017-05-08 | $26.65M 10-Q · filed 2016-05-16 | $52.51M derived: sum of 2 quarters · filed 2017-05-08 | $94.31M derived: sum of 3 quarters · filed 2017-05-08 | $222.73M derived: sum of 4 quarters · filed 2017-05-08 | |||
| 2015-12-31 | $25.84M 10-K · filed 2016-03-30 | $67.65M derived: sum of 2 quarters · filed 2016-11-10 | $196.06M derived: sum of 3 quarters · filed 2016-11-10 | $227.68M 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | $41.81M 10-Q · filed 2016-11-10 | $38.85M 10-Q · filed 2015-11-12 | $170.22M derived: sum of 2 quarters · filed 2016-11-10 | $201.81M 10-Q · filed 2016-11-10 | $152.85M 10-Q · filed 2015-11-12 | $203.67M derived: sum of 4 quarters · filed 2016-11-10 | ||
| 2015-06-30 | $128.41M 10-Q · filed 2016-08-15 | $82.43M 10-Q · filed 2015-09-10 | $160.03M 10-Q · filed 2016-08-15 | $114.02M 10-Q · filed 2015-09-10 | $161.86M derived: sum of 3 quarters · filed 2016-08-15 | $162.58M derived: sum of 4 quarters · filed 2016-08-15 | ||
| 2015-03-31 | $31.62M 10-Q · filed 2016-05-16 | $33.44M derived: sum of 2 quarters · filed 2016-05-16 | $34.17M derived: sum of 3 quarters · filed 2016-05-16 | $35.25M derived: sum of 4 quarters · filed 2016-05-16 | ||||
| 2014-12-31 | $1.83M 10-K · filed 2016-03-30 | $2.55M derived: sum of 2 quarters · filed 2016-03-30 | $3.63M derived: sum of 3 quarters · filed 2016-03-30 | $4.62M 10-K · filed 2017-03-15 | ||||
| 2014-09-30 | $724.00K 10-K · filed 2016-03-30 | $702.00K 10-Q · filed 2015-11-12 | $1.80M derived: sum of 2 quarters · filed 2016-03-30 | $2.81M 10-Q · filed 2015-11-12 | ||||
| 2014-06-30 | $1.08M 10-K · filed 2016-03-30 | $1.05M 10-Q · filed 2015-09-10 | $2.11M 10-Q · filed 2015-09-10 | |||||
| 2014-03-31 | $992.00K 10-K · filed 2016-03-30 | |||||||
| 2013-12-31 | $2.42M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |